RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation treatment planning system (TPS) and RayCare oncology information system (OIS). The first customer will be Advanced Oncotherapy plc (AVO), a U.K.-based developer of next-generation proton therapy technology. AVO will use it for the first LIGHT (Linac Image Guided Hadron Technology) system at the proton therapy facility under construction at Harley Street in central London, U.K.

iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI. The solution built on artificial intelligence (AI) is now available to healthcare facilities in the U.S.

U.S. Electronics Inc. (USEI) recently announced the release of what it calls the world’s first Windows-compatible medical display viewing solution leveraging high-quality iPad displays, ideal for clinical review and reference monitors for patient review. The dual monitor workstation offers the smallest form factor viewing of 3MP medical images and comes with USEI’s XR-Vue viewing software. The product enables a cost-effective workstation without the need to purchase high-cost 3MP monitors. The iPad viewing solution will work on any Windows OS computer.

During the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 25-30 in Chicago, Siemens Healthineers introduced the Magnetom Altea 1.5 Tesla (1.5T) magnetic resonance (MR) scanner, equipped with BioMatrix patient personalization technology.

GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate the development and adoption of artificial intelligence (AI) technology and empower providers to deliver faster, more precise care. Edison is part of GE Healthcare’s $1 billion and growing Digital portfolio and will serve as a “digital thread” for its existing AI partnerships and products. Clinical partners will use Edison to develop algorithms, and technology partners will work with GE Healthcare to bring the latest advancements in data processing to Edison applications and smart devices.

Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle Medical also recently secured approval to affix the CE Mark on SubtlePET to begin marketing in the European Economic Area without restrictions.